Point-of-Care Molecular Testing Nearly Doubles Appropriate Treatment for Vaginitis, Randomized Trial Shows
核心洞察
A randomized trial of 276 women found that point-of-care NAAT (Xpert Xpress MVP (搜索)) raised appropriate treatment within 24 hours to 83.2%, versus 51.3% with usual care (P < 0.001).
Among women with no detectable vaginal pathogens, unnecessary antimicrobial treatment fell from 50.0% in usual care to 27.1% in the POC NAAT arm (P = 0.031).
Wet mount microscopy showed limited sensitivity (50% for Candida and TV, 63% for BV), while 87% of providers said they would adopt POC NAAT in routine practice.
A randomized clinical trial has demonstrated that integrating a point-of-care (POC) nucleic acid amplification test (NAAT) into routine care significantly improves the appropriateness of treatment for women presenting with symptoms of vaginitis and vaginosis. The study, led by investigators at Magee-Womens Research Institute (搜索) and the University of Pittsburgh and supported by an investigator-initiated grant from Cepheid, found that women tested with the Xpert Xpress Multiplex Vaginal Panel (MVP) were far more likely to receive appropriate treatment within 24 hours of their clinic visit compared with those receiving usual care.
The trial (clinicaltrials.gov NCT06438575), conducted between July 2024 and March 2025, enrolled 276 women with vaginitis symptoms, randomized 1:1 to usual care (137 women) or POC NAAT (139 women). Appropriate treatment, defined as receipt of CDC-recommended or FDA-approved therapy based on concordant NAAT results, was provided to 61 of 119 women (51.3%) in the usual care group versus 104 of 125 women (83.2%) in the POC NAAT group (P < 0.001).
Diagnostic Accuracy and Overtreatment
The study also quantified the problem of unnecessary antimicrobial prescribing. Among women confirmed to have no detectable vaginal pathogens, 50.0% in the usual care arm received inappropriate antifungal or antibiotic treatment, compared with 27.1% in the POC NAAT arm (P = 0.031). "Overuse of antimicrobials when no pathogens are detected should be avoided since it can contribute to antimicrobial resistance, may disrupt the vaginal microbiome, may cause side effects and adds costs to women and their insurers," the study authors noted.
The limitations of traditional diagnostic methods were a central finding. Wet mount microscopy, a mainstay of vaginitis diagnosis for more than 50 years, showed a sensitivity of only 50.0% for Candida and 50.0% for Trichomonas vaginalis (搜索), and 62.9% for bacterial vaginosis (搜索) (BV) in the usual care group. The investigators reported that 25% of providers relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections only about 50–63% of the time.
Test Performance and Study Design
The Xpert Xpress MVP (搜索) is an FDA-cleared, CLIA-waived PCR test that detects DNA targets from anaerobic bacteria associated with BV, Candida species associated with vulvovaginal candidiasis (搜索) (VVC), and Trichomonas vaginalis (搜索), providing results in approximately one hour. In the trial, testing was performed on-site by non-laboratory research staff after brief training. The MVP results were compared against the BD MAX Vaginal Panel, a laboratory-based NAAT used to define true positives and negatives. Overall, 244 of 276 tests (88.2%) were concordant on both platforms.
Based on concordant NAAT results, any vaginitis/vaginosis was detected in 154 (63.1%) of symptomatic women, while 90 (36.9%) had no positive results. BV was detected in 44.7%, Candida species in 32.0%, and TV in 5.1% of the study population.
Provider Perspectives
Provider surveys before and after the trial revealed a notable shift in attitudes. At baseline, 82% of providers relying on wet mount/Amsel criteria reported satisfaction with turnaround time and 86% expressed confidence in the accuracy of the method. However, following the trial, among the 53 providers who had a patient in the POC NAAT group, 98% were satisfied with the turnaround time, 85% were satisfied with the workflow, and 87% stated they would like to include POC NAAT in their practice in the future.
Commenting on the findings, Connie Savor, MD, Chief Medical Officer at Cepheid, said: "Women presenting with vaginal symptoms deserve accurate answers and timely, evidence-based care. This study demonstrates how molecular point-of-care tests, such as Xpert Xpress MVP (搜索), can help clinicians make more informed treatment decisions in a single visit, improving care while reducing unnecessary treatment."
Clinical Significance
This study is the first randomized clinical trial to evaluate the utility of a multiplex molecular test for vaginitis at the point of care. The authors note that the 2020 American College of Obstetrics and Gynecology guidelines for BV indicated that NAATs could replace wet mount if proven to have clinical utility. The present randomized clinical utility study demonstrates that integration of POC NAATs in clinics serving women with vaginitis symptoms can significantly improve the appropriateness of treatment compared with usual care.
A limitation acknowledged by the authors was the low prevalence of TV in the study population, which limited the ability to detect differences between the usual care and POC NAAT groups for this pathogen. Additionally, the 1-month follow-up limited the capacity to assess whether inappropriate treatment resulted in a greater number of follow-up visits for persistent or recurrent symptoms.